Company & Sponsor Intelligence
Impax Laboratories, LLC
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting1
Completed2
Countries1
Therapeutic footprint
migraine_headacheparkinsons
Indexed studies
NCT00253084Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease
parkinsons · United StatesPHASE2
parkinsons · United StatesPHASE2
NCT03275922Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE
migraine_headache · United StatesPHASE3
migraine_headache · United StatesPHASE3
NCT06765668A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
parkinsons · United StatesPHASE4
parkinsons · United StatesPHASE4
Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →